Summary: Maria Vähätupa, Ph.D. is appointed to Director of In Vivo Pharmacology at our Kuopio, Finland site as of October 2020.
Kuopio, FINLAND, Vilnius, LITHUANIA, Forest Park, IL, USA, Marseille, FRANCE, and Shanghai, P.R. CHINA – October 12th, 2020 – Experimentica Ltd., a leader in preclinical ophthalmic drug discovery services, announces today the appointment of Maria Vähätupa, Ph.D., to the position of Director of In Vivo Pharmacology at their headquarter in Kuopio, Finland.
Dr. Vähätupa holds a Ph.D. degree in Biomedicine from Tampere University, Finland. She joined Experimentica Ltd. as a project researcher in angiogenesis-related studies in 2015. In 2019, Dr. Vähätupa took a role of in vivo team project coordinator and senior scientist. In September 2020, she was appointed as Director of In Vivo Pharmacology at our Kuopio site.
Dr. Vähätupa has a track-record of peer-reviewed publications in the field of pathologic angiogenesis in retina, vascular permeability and carcinogenesis.
Dr. Giedrius Kalesnykas, President and CEO of Experimentica Ltd., commented: “Professional development at all career stages and our ability to retain talent are among Experimentica’s top priorities. Today I am particularly excited to announce that Maria is promoted to Director of In Vivo Pharmacology at our site in Finland.”
About Experimentica Ltd.:
Experimentica Ltd. is a global contract research organization (CRO) that specializes in preclinical models of ophthalmic disease. Our world-class scientists and technicians apply a comprehensive set of skills and industry experience to model ocular diseases using multiple experimental platforms, from cell culture-based systems to complex surgical techniques and in vivo models. With R&D laboratory sites in Kuopio, Finland, Vilnius, Lithuania, and Grand Rapids, Michigan, USA, global representation and an industry-leading portfolio, Experimentica Ltd. delivers the highest quality science to assist clients around the globe in advancing their ophthalmic drug discovery and drug development portfolio.
Contact for media enquiries:
Simon Kaja, Ph.D., Chief Scientific Officer and Vice-President, Americas
Phone: +1 (682) 234-4763
Guillaume Demarne, Pharm.D., Director, Business Development
Phone: +33 (0) 7 83 55 69 52